Meet team Cerba Research at the Immunogenicity and Bioassay Summit in Washington DC from October 15-18.
Resolve the challenges of immunogenicity testing and risk assessment during preclinical and clinical development, bioassay design & analysis, and how to manipulate the immune system for therapeutic advantage by attending CHI’s 16th Annual Immunogenicity & Bioassay Summit.
Engage with our team of experts to discuss the latest scientific, regulatory, and innovative insights on:
• Bioanalytical assay development/validation services for large molecules, biologics and biosimilars
• Biomarker services
• (Early-stage) Immunogenicity testing services for vaccines, biologics and gene therapies
• Supporting services, including global central laboratory and logistics capabilities
• …. and more
Make sure to attend our speaking slot: Tailoring ADA and NAb assays to different drug modalities: Insights from case studies
Abstract: The presentation will focus on key analytical parameters when setting up ADA and NAb assays specifically dependent on the type of drug product administered to patients. An overview of various approaches for ADA and NAb assays will be provided. Two case studies will highlight issues encountered when in the presence of pre-existing Ab, high signals causing hook effect and matrix effect. Approaches taken to resolve these challenges will be presented.
Meet us at booth nr.12 or click HERE to learn more about our bioanalysis services.